<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865109</url>
  </required_header>
  <id_info>
    <org_study_id>232-SM-901</org_study_id>
    <nct_id>NCT02865109</nct_id>
  </id_info>
  <brief_title>Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)</brief_title>
  <official_title>Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular&#xD;
      Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The nusinersen expanded access program (EAP) is available at approved treatment centers in&#xD;
      select territories.&#xD;
&#xD;
      A doctor must decide whether nusinersen treatment is appropriate for each patient, based on&#xD;
      the patient's medical history and program eligibility criteria. A full list of participating&#xD;
      treatment centers is provided in the 'Contacts and Locations' section of this listing, and is&#xD;
      regularly updated.&#xD;
&#xD;
      Following local approval and official reimbursement of nusinersen in each territory, the EAP&#xD;
      will close and patients will transfer to commercially available drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Infantile-onset Spinal Muscular Atrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen</intervention_name>
    <description>Administered by intrathecal injection</description>
    <other_name>ISIS 396443</other_name>
    <other_name>BIIB058</other_name>
    <other_name>Spinraza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or&#xD;
             compound heterozygote.&#xD;
&#xD;
          -  Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with&#xD;
             infantile onset, Type I SMA&#xD;
&#xD;
          -  Patient whose care in the opinion of the treating physician meets, and is expected to&#xD;
             continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard&#xD;
             of Care in SMA&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patient is qualified to participate in an ongoing clinical trial with nusinersen&#xD;
&#xD;
          -  Participation in a prior nusinersen study&#xD;
&#xD;
          -  Previous exposure to nusinersen&#xD;
&#xD;
          -  History of brain or spinal cord disease that would interfere with the LP procedures or&#xD;
             CSF circulation&#xD;
&#xD;
          -  Presence of implanted shunt for the drainage of CSF or implanted CNS catheter&#xD;
&#xD;
          -  Previous or current participation in a clinical trial with an investigational gene&#xD;
             therapy for SMA&#xD;
&#xD;
          -  Participation in a study with an investigational therapy for SMA within 6 months or&#xD;
             five half-lives of the investigational drug, whichever is the longer, prior to the&#xD;
             first dose of nusinersen.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland District Health Board ADHB</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes University Hospital</name>
      <address>
        <city>Kayseri</city>
        <state>Anatolia</state>
        <zip>38000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <state>Central Anatolia</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Uni. Research &amp; Educational Hospital</name>
      <address>
        <city>Kadıköy</city>
        <state>Istanbul</state>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipol University Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Marmara</state>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>New Zealand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS-SMN Rx</keyword>
  <keyword>ISIS 396443</keyword>
  <keyword>ISIS-396443</keyword>
  <keyword>ENDEAR</keyword>
  <keyword>IONIS-SMNRx</keyword>
  <keyword>IONIS-SMN Rx</keyword>
  <keyword>EMBRACE</keyword>
  <keyword>NURTURE</keyword>
  <keyword>IONIS</keyword>
  <keyword>BIOGEN</keyword>
  <keyword>SHINE</keyword>
  <keyword>Nusinersen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

